SEARCH

SEARCH BY CITATION

Current Awareness

  • 1. Reviews
  • Adolph E, Chatterjee T, Ince H, Eckard H, Rehders T, Kische S, Drawert S, Petzsch M, Nienaber CA. Contrast-media-induced nephrotoxicity - Clinic and prevention (German, English Abstract). Dtsch Med Wochenschr 130, 2391-2396 (2005)
  • Couturier O, Leost F, Campone M, Carlier T, Chatal JF, Hustinx R. Is 3′-deoxy-3′-[18F] flurothymidine ([18F]-FLT) the next tracer for routine clinical PET after R [18F]-FDG? (French, English Abstract). Bull Cancer 92, 789-798 (2005)
  • Dharmarajan S, Schuster DP. Molecular imaging of the lungs. Acad Radiol 12, 1394-1405 (2005)
  • Eckelman WC, Rohatagi S, Krohn KA, Vera DR. Are there lessons to be learned from drug development that will accelerate the use of molecular imaging probes in the clinic?. Nucl Med Biol 32, 657-662 (2005)
  • Frank GK, Kaye WH. Positron emission tomography studies in eating disorders: Multireceptor brain imaging, correlates with behavior and implications for pharmacotherapy. Nucl Med Biol 32, 755-761 (2005)
  • Krohn KA, Mankoff DA, Muzi M, Link JM, Spence AM. True tracers: Comparing FDG with glucose and FLT with thymidine. Nucl Med Biol 32, 663-671 (2005)
  • Kung MP, Kung HF. Mass effect of injected dose in small rodent imaging by SPECT and PET. Nucl Med Biol 32, 673-678 (2005)
  • Ma B, Hankenson KD, Dennis JE, Caplan AI, Goldstein SA, Kilbourn MR. A simple method for stem cell labeling with fluorine 18. Nucl Med Biol 32, 701-705 (2005)
  • Manninen HI, Yang XM. Imaging after vascular gene therapy. Eur J Radiol 56, 165-170 (2005)
  • Miyawaki A. Innovations in the imaging of brain functions using fluorescent proteins. Neuron 48, 189-199 (2005)
  • Parfrey P. The clinical epidemiology of contrast-induced nephropathy. Cardiovasc Intervent Radiol 28, S3-S11 (2005)
  • Smith CJ, Volkert WA, Hoffman TJ. Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes. Nucl Med Biol 32, 733-740 (2005)
  • Stacul F. Reducing the risks for contrast-induced nephropathy. Cardiovasc Intervent Radiol 28, S12-S18 (2005)
  • Strobel K, Thuerl CM, Hany TF. How much intravenous contrast is needed in FDG-PET/CT?. Nuklearmedizin 44, S32-S37 (2005)
  • Tombach B, Reimer P. Soluble paramagnetic chelates and iron oxides as contrast agents for stabilized colloidal particle solutions of magnetic resonance imaging. Curr Medicinal Chem 12, 2795-2804 (2005)
  • Vera DR, Hall DJ, Hoh CK, Gallant P, McIntosh LM, Mattrey RF. Cy5.5-DTPA-galactosyl-dextran: A fluorescent probe for in vivo measurement of receptor biochemistry. Nucl Med Biol 32, 687-693 (2005)
  • Wunder A, Straub RH, Gay S, Funk J, Muller-Ladner U. Molecular imaging: Novel tools in visualizing rheumatoid arthritis. Rheumatology 44, 1341-1349 (2005)
  • Contrast Agents: 3. Chemistry
  • Aime S, Dastru W, Gobetto R, Viale A. para-Hydrogenation of unsaturated moieties on poly(lysine) derived substrates for the development of novel hyperpolarized MRI contrast agents. Org Biomol Chem 3, 3948-3954 (2005)
  • Allen M, Bulte JWM, Liepold L, Basu G, Zywicke HA, Frank JA, Young M, Douglas T. Paramagnetic viral nanoparticles as potential high-relaxivity magnetic resonance contrast agents. Magn Reson Med 54, 807-812 (2005)
  • Calabi L, Biondi L, De Miranda M, Ghelli S, Mora C, Paleari L, Rebaudengo C, Umbelli C. 1H and 13C spectral assignments of an oxytocin-DTPA derivative, a ligand for potential receptor-specific MRI contrast agents. Magn Reson Chem 43, 654-657 (2005)
  • Mishkin D, Carpenter S, Croffie J, Chuttani R, DiSario J, Hussain N, Liu J, Somogyi L, Tierney W, Petersen BT. ASGE Technology Status Evaluation Report: Radiographic contrast media used in ERCP. Gastrointest Endosc 62, 480-484 (2005)
  • Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 40, 715-724 (2005)
  • Schomacker K, Dietlein M, Modder G, Boddenberg-Patzold B, Zimmermanns B, Fischer T, Schicha H. Stability of radioactive colloids for radiation synovectomy: Influence of X-ray contrast agents, anaesthetics and glucocorticoids in vitro. Nucl Med Commun 26, 1027-1035 (2005)
  • Strijkers GJ, Mulder WJM, Van Heeswijk RB, Frederik PM, Bomans P, Magusin PCMM, Nicolay K. Relaxivity of liposomal paramagnetic MRI contrast agents. MAGMA 18, 186-192 (2005)
  • Thilmann O, Larsson EM, Bjorkman-Burtscher IM, Stahlberg F, Wirestam R. Comparison of contrast agents with high molarity and with weak protein binding in cerebral perfusion imaging at 3 T. J Magn Reson Imaging 22, 597-604 (2005)
  • Zhang ZD, Greenfield MT, Spiller M, McMurry TJ, Lauffer RB, Caravan P. Multilocus binding increases the relaxivity of protein-bound MRI contrast agents. Angew Chem Int Ed 44, 6766-6769 (2005)
  • 4. Technique
  • Balvay D, Frouin F, Calmon G, Bessoud B, Kahn E, Siauve N, Clement O, Cuenod CA. New criteria for assessing fit quality in dynamic contrast-enhanced T1-weighted MRI for perfusion and permeability imaging. Magn Reson Med 54, 868-877 (2005)
  • Boppart SA, Oldenburg AL, Xu CY, Marks DL. Optical probes and techniques for molecular contrast enhancement in coherence imaging. J Biomed Opt 10, 41208 (2005)
  • Born M, Willinek WA, Gieseke J, Von Falkenhausen M, Schild H, Kuhl CK. Sensitivity encoding (SENSE) for contrast enhanced 3D MR angiography of the abdominal arteries. J Magn Reson Imaging 22, 559-565 (2005)
  • De Monye C, Cademartiri F, De Weert TT, Siepman DAM, Dippel DWJ, Van Der Lugt A. Sixteen-detector row CT angiography of carotid arteries: Comparison of different volumes of contrast material with and without a bolus chaser. Radiology 237, 555-562 (2005)
  • Di Bella EVR, Parker DL, Sinusas AJ. On the dark rim artifact in dynamic contrast-enhanced MRI myocardial perfusion studies. Magn Reson Med 54, 1295-1299 (2005)
  • Droste DW, Boehm T, Ritter MA, Dittrich R, Ringelstein EB. Benefit of echocontrast-enhanced transcranial arterial color-coded duplex ultrasound. Cerebrovasc Dis 20, 332-336 (2005)
  • Gebauer B, Teichgraber UKM, Hothan T, Felix R, Wagner HJ. Contrast media power injection using central venous port catheters results of an in vitro study (German, English Abstract). Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 177, 1417-1423 (2005)
  • Heller F, Schwaiger A, Eymael R, Schulz-Wendtland R, Blumich B. Measuring the contrast-enhancement in the skin and subcutaneous fatty tissue with the NMR-MOUSE®: A feasibility study (German, English Abstract). Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 177, 1412-1416 (2005)
  • Hsiang D, Shah N, Yu H, Su MY, Cerussi A, Butler J, Baick C, Mehta R, Nalcioglu O, Tromberg B. Coregistration of dynamic contrast enhanced MRI and broadband diffuse optical spectroscopy for characterizing breast cancer. Technol Cancer Res Treat 4, 549-558 (2005)
  • Hu HH, Madhuranthakam AJ, Kruger DG, Glockner JF, Riederer SJ. Continuously moving table MRI with SENSE: Application in peripheral contrast enhanced MR angiography. Magn Reson Med 54, 1025-1031 (2005)
  • Kellman P, Chung YC, Simonetti OP, McVeigh ER, Arai AE. Multicontrast delayed enhancement provides improved contrast between myocardial infarction and blood pool. J Magn Reson Imaging 22, 605-613 (2005)
  • Kim JK, Hong SS, Choi YJ, Park SH, Ahn H, Kim CS, Cho KS. Wash-in rate on the basis of dynamic contrast-enhanced MRI: Usefulness for prostate cancer detection and localization. J Magn Reson Imaging 22, 639-646 (2005)
  • Licha K, Debus N, Emig-Vollmer S, Hofmann B, Hasbach M, Stibenz D, Sydow S, Schirner M, Ebert B, Petzelt D, Buhrer C, Semmler W, Tauber R. Optical molecular imaging of lymph nodes using a targeted vascular contrast agent. J Biomed Opt 10, 41205 (2005)
  • Manninger SP, Muldoon LL, Nesbit G, Murillo T, Jacobs PM, Neuwelt EA. An exploratory study of ferumoxtran-10 nanoparticles as a blood-brain barrier imaging agent targeting phagocytic cells in CNS inflammatory lesions. Am J Neuroradiol 26, 2290-2300 (2005)
  • Meyer BC, Ribbe C, Kruschewski M, Wolf KJ, Albrecht T. 16-row multidetector CT angiography of the aortoiliac system and lower extremity arteries: Contrast enhancement and image quality using a standardized examination protocol (German, English Abstract). Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 177, 1562-1570 (2005)
  • Passamonti M, Vercelli A, Azzaretti A, Rodolico G, Calliada F. Characterization of focal liver lesions with a new ultrasound contrast agent using continuous low acoustic power imaging: Comparison with contrast enhanced spiral CT (Italian, English Abstract). Radiol Med (Torino) 109, 358-369 (2005)
  • Renault G, Tranquart F, Perlbarg V, Bleuzen A, Herment A, Frouin F. A posteriori respiratory gating in contrast ultrasound for assessment of hepatic perfusion. Phys Med Biol 50, 4465-4480 (2005)
  • Salomir R, Palussiere J, Fossheim SL, Rogstad A, Wiggen UN, Grenier N, Moonen CTW. Local delivery of magnetic resonance (MR) contrast agent in kidney using thermosensitive liposomes and MR imaging-guided local hyperthermia: A feasibility study in vivo. J Magn Reson Imaging 22, 534-540 (2005)
  • Sitek A, Sheiman RG. Small-bowel perfusion measurement: Feasibility with single-compartment kinetic model applied to dynamic contrast-enhanced CT. Radiology 237, 670-674 (2005)
  • Walczak P, Kedziorek DA, Gilad AA, Lin S, Bulte JWM. Instant MR labeling of stem cells using magnetoelectroporation. Magn Reson Med 54, 769-774 (2005)
  • Zaitsev M, D'Arcy J, Collins DJ, Leach MO, Zilles K, Shah NJ. Dual-contrast echo planar imaging with keyhole: Application to dynamic contrast-enhanced perfusion studies. Phys Med Biol 50, 4491-4505 (2005)
  • 5. Experimental
  • Buecker A, Katoh M, Krombach GA, Spuentrup E, Bruners P, Gunther RW, Niendorf TF, Mahnken AH. A feasibility study of contrast enhancement of acute myocardial infarction in multislice computed tomography - Comparison with magnetic resonance imaging and gross morphology in pigs. Invest Radiol 40, 700-704 (2005)
  • Granot D, Kunz-Schughart LA, Neeman M. Labeling fibroblasts with biotin-BSA-GdDTPA-FAM for tracking of tumor-associated stroma by fluorescence and MR imaging. Magn Reson Med 54, 789-797 (2005)
  • Kleinschnitz C, Schutz A, Nolte I, Horn T, Frank M, Solymosi L, Stoll G, Bendszus M. In vivo detection of developing vessel occlusion in photothrombotic ischemic brain lesions in the rat by iron particle enhanced MRI. J Cereb Blood Flow Metab 25, 1548-1555 (2005)
  • Kwak HS, Lee YH, Han YM, Jin GY, Kim W, Chung GH. Comparison of renal damage by iodinated contrast or gadolinium in an acute renal failure rat model based on serum creatinine levels and apoptosis degree. J Korean Med Sci 20, 841-847 (2005)
  • Li KL, Wilmes LJ, Henry RG, Pallavicini MG, Park JW, Hu-Lowe DD, McShane TM, Shalinsky DR, Fu YJ, Brasch RC, Hylton NM. Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: Assessment by voxel analysis of dynamic contrast-enhanced MRI. J Magn Reson Imaging 22, 511-519 (2005)
  • Lim GY, Im SA, Jung WS, Lee JM, Lee AW. Evaluation of joint effusion in rabbits by color Doppler, power Doppler, and contrast-enhanced power Doppler ultrasonography. J Clin Ultrasound 33, 333-338 (2005)
  • Liu YT, D'Arceuil H, He JL, Duggan M, Seri S, Hashiguchi Y, Nakatani A, Gonzelez RG, Pryor J, De Crespigny A. Dynamic susceptibility contrast perfusion imaging of cerebral ischemia in nonhuman primates: Comparison of Gd-DTPA and NMS60. J Magn Reson Imaging 22, 461-466 (2005)
  • Maruyama H, Matsutani S, Saisho H, Kamiyama N, Mine Y, Hirata T, Sasamata M. Sonographic shift of hypervascular liver tumor on blood pool harmonic images with definity: Time-related changes of contrast-enhanced appearance in rabbit VX2 tumor under extra-low acoustic power. Eur J Radiol 56, 60-65 (2005)
  • Planchamp C, Pastor CM, Balant L, Becker CD, Terrier F, Gex-Fabry M. Quantification of Gd-BOPTA uptake and biliary excretion from dynamic magnetic resonance imaging in rat livers - Model validation with 153Gd-BOPTA. Invest Radiol 40, 705-714 (2005)
  • Preda A, Novikov V, Muglich M, Floyd E, Turetschek K, Shames DM, Roberts TPL, Corot C, Carter WO, Brasch RC. Magnetic resonance characterization of tumor microvessels in experimental breast tumors using a slow clearance blood pool contrast agent (carboxymethyldextran-A2-Gd-DOTA) with histopathological correlation. Eur Radiol 15, 2268-2275 (2005)
  • Spilker ME, Seng KY, Yao AA, Daldrup-Link HE, Shames DM, Brasch RC, Vicini P. Mixture model approach to tumor classification based on pharmacokinetic measures of tumor permeability. J Magn Reson Imaging 22, 549-558 (2005)
  • Thoeny HC, De Keyzer F, Vandecaveye V, Chen F, Sun XH, Bosmans H, Hermans R, Verbeken EK, Boesch C, Marchal G, Landuyt W, Ni Y. Effect of vascular targeting agent in rat tumor model: Dynamic contrast-enhanced versus diffusion-weighted MR imaging. Radiology 237, 492-499 (2005)
  • Thuen M, Singstad TE, Pedersen TB, Haraldseth O, Berry M, Sandvig A, Brekken C. Manganese-enhanced MRI of the optic visual pathway and optic nerve injury in adult rats. J Magn Reson Imaging 22, 492-500 (2005)
  • Van Camp N, Peeters RR, Van der Linden A. A comparison between blood oxygenation level dependent and cerebral blood volume contrast in the rat cerebral and cerebellar somatosensoric cortex during electrical paw stimulation. J Magn Reson Imaging 22, 483-491 (2005)
  • 6. Applications
  • Abe Y, Muro T, Sakanoue Y, Komatsu R, Otsuka M, Naruko T, Itoh A, Yoshiyama M, Haze K, Yoshikawa J. Intravenous myocardial contrast echocardiography predicts regional and global left ventricular remodelling after acute myocardial infarction: Comparison with low dose dobutamine stress echocardiography. Heart 91, 1578-1583 (2005)
  • Anderson DR, Kovacs MJ, Dennie C, Kovacs G, Stiell I, Dreyer I, McCarron B, Pleasance S, Burton E, Cartier Y, Wells PS. Use of spiral computed tomography contrast angiography and ultrasonography to exclude the diagnosis of pulmonary embolism in the emergency department. J Emerg Med 29, 399-404 (2005)
  • Asaumi J, Hisatomi M, Yanagi Y, Matsuzaki H, Choi YS, Kawai N, Konouchi H, Kishi K. Assessment of ameloblastomas using MRI and dynamic contrast-enhanced MRI. Eur J Radiol 56, 25-30 (2005)
  • Barkhof F, Held U, Simon JH, Daumer M, Fazekas F, Filippi M, Frank JA, Kappos L, Li D, Menzler S, Miller DH, Petkau J, Wolinsky J. Predicting gadolinium enhancement status in MS patients eligible for randomized clinical trials. Neurology 65, 1447-1454 (2005)
  • Belcik JT, Bierig SM, Chadwell K, Roberts B. Clinical application of harmonic power Doppler imaging in the assessment of myocardial perfusion by contrast echocardiography. J Am Soc Echocardiogr 18, 1083-1092 (2005)
  • Deda H, Erden I, Yagmurlu B. Evaluation of petrosal sinus patency with 3-dimensional contrast-enhanced magnetic resonance venography in petroclival meningiomas for surgical strategy. Surg Neurol 64, S67-S71 (2005)
  • Doelman C, Duijm LEM, Liem YS, Froger CL, Tielbeek AV, Donkers-van Rossum AB, Cuypers PWM, Douwes-Draaijer P, Buth J, Van den Bosch HCM. Stenosis detection in failing hemodialysis access fistulas and grafts: Comparison of color Doppler ultrasonography, contrast-enhanced magnetic resonance angiography, and digital subtraction angiography. J Vasc Surg 42, 739-746 (2005)
  • Elliott MD, Kim RJ. Late gadolinium cardiovascular magnetic resonance in the assessment of myocardial viability. Coron Artery Dis 16, 365-372 (YR)
  • Espinosa LA, Daniel BL, Vidarsson L, Zakhour M, Ikeda DM, Herfkens RJ. The lactating breast: Contrast-enhanced MR imaging of normal tissue and cancer. Radiology 237, 429-436 (2005)
  • Farber E, Fischer D, Eliakim R, Beck-Razi N, Engel A, Veitsman E, Chermesh I, Yassin K, Gaitini D, Libes M, Linn S, Soboh S, Baruch Y. Esophageal varices: Evaluation with esophagography with barium versus endoscopic gastroduodenoscopy in patients with compensated cirrhosis - Blinded prospective study. Radiology 237, 535-540 (2005)
  • Farina R, Pennisi F, Midiri M, Belfiore G, La Rosa M, Pennisi M, Arena C, Ettorre GC. The color Doppler with contrast agent US in the study of post cholecystectomy syndrome (Italian, English Abstract). Radiol Med (Torino) 109, 532-539 (2005)
  • Futterer JJ, Engelbrecht MR, Huisman HJ, Jager GJ, Hulsbergen-van de Kaa CA, Witjes JA, Barentsz JO. Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: Experienced versus less experienced readers. Radiology 237, 541-549 (2005)
  • Goyen M, Edelman M, Perreault P, O'Riordan E, Bertoni H, Taylor J, Siragusa D, Sharafuddin M, Mohler ER, Breger R, Yucel EK, Shamsi K, Weisskoff RM. MR angiography of aortoiliac occlusive disease: A phase III study of the safety and effectiveness of the blood-pool contrast agent MS-325. Radiology 236, 825-833 (2005)
  • Guo SZ, Shu XH, Pan CZ, Li YL, Ge JB, Chen HZ. Usefulness of dobutamine stress mycocardial contrast echocardiography for assessing coronary artery disease. Chin Med J (Engl) 118, 1766-1772 (2005)
  • Hagspiel K, Butty S, Nandalur KR, Bissonette EA, Shih MCP, Leung DA, Angle JF, Spinosa DJ, Matsumoto AH, Ahmed H, Sanfey H, Isaacs RB, Sawyer RG, Pruett TL. Magnetic resonance urography for the assessment of potential renal donors: Comparison of the RARE technique with a low-dose gadolinium-enhanced magnetic resonance urography technique in the absence of pharmacological and mechanical intervention. Eur Radiol 15, 2230-2237 (2005)
  • Handke M, Harloff A, Hetzel A, Olschewski M, Bode C, Geibel A. Predictors of left atrial spontaneous echocardiographic contrast or thrombus formation in stroke patients with sinus rhythm and reduced left ventricular function. Am J Cardiol 96, 1342-1344 (2005)
  • Hsu HL, Chen CJ. Extensive cerebrospinal fluid enhancement following gadolinium chelate administration: Possible pathogenesis. Acta Radiol 46, 523-527 (2005)
  • Ishida M, Sakuma H, Kato N, Ishida N, Kitagawa K, Shimono T, Yada I, Takeda K. Contrast-enhanced MR imaging for evaluation of coronary artery disease before elective repair of aortic aneurysm. Radiology 237, 458-464 (2005)
  • Jain R, Sawhney S. Contrast-enhanced MR angiography (CE-MRA) in the evaluation of vascular complications of renal transplantation. Clin Radiol 60, 1171-1181 (2005)
  • Jung EM, Jungius KP, Rupp N, Gallegos M, Ritter G, Lenhart M, Clevert DA, Kubale R. Contrast enhanced harmonic ultrasound for differentiating breast tumors - First results. Clin Hemorheol Microcirc 33, 109-120 (2005)
  • Jung G, Poll L, Cohen M, Saleh A, Vogler H, Wettstein M, Willers R, Modder U, Koch JA. Differential diagnosis of focal liver lesions using contrast-enhanced MRI with SHU 555 A in comparison with unenhanced MRI and multidetector spiral-CT (German, English Abstract). Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 177, 1571-1577 (2005)
  • Kawamura H, Abe Y, Hasuo K, Ueno N. Diagnosis of hemorrhage from the gallbladder with the use of contrast-enhanced sonography. J Ultrasound Med 24, 1583-1586 (2005)
  • Kim CK, Choi DG, Lim HK, Kim SH, Lee WJ, Kim MJ, Lee JY, Jeon YH, Lee J, Lee SJ, Lim JH. Therapeutic response assessment of percutaneous radiofrequency ablation for hepatocellular carcinoma: Utility of contrast-enhanced agent detection imaging. Eur J Radiol 56, 66-73 (2005)
  • Klauser A, Demharter J, De Marchi A, Sureda D, Barile A, Masciocchi C, Faletti C, Schirmer M, Kleffel T, Bohndorf K. Contrast enhanced gray-scale sonography in assessment of joint vascularity in rheumatoid arthritis: Results from the IACUS study group. Eur Radiol 15, 2404-2410 (2005)
  • Liauw SL, Amdur RJ, Mendenhall WM, Palta J, Kim S. The effect of intravenous contrast on intensity-modulated radiation therapy dose calculations for head and neck cancer. Am J Clin Oncol 28, 456-459 (2005)
  • Ludemann L, Grieger W, Wurm R, Wust P, Zimmer C. Quantitative measurement of leakage volume and permeability in gliomas, meningiomas and brain metastases with dynamic contrast-enhanced MRI. Magn Reson Imaging 23, 833-841 (2005)
  • Lutz AM, Willmann JK, Goepfert K, Marincek B, Weishaupt D. Hepatocellular carcinoma in cirrhosis: Enhancement patterns at dynamic gadolinium-and superparamagnetic iron oxide-enhanced T1-weighted MR imaging. Radiology 237, 520-528 (2005)
  • Mariano MN, Van den Bosch MAAJ, Daniel BL, Nowels KW, Birdwell RL, Fong KJ, Desmond PS, Plevritis S, Stables LA, Zakhour M, Herfkens RJ, Ikeda DM. Contrast-enhanced MRI of ductal carcinoma in situ: Characteristics of a new intensity-modulated parametric mapping technique correlated with histopathologic findings. J Magn Reson Imaging 22, 520-526 (2005)
  • McMahon CJ, Ayres NA, Bezold LI, Lewin MB, Alonzo M, Altman CA, Kovalchin JP, Eidem BW, Pignatelli RH. Safety and efficacy of intravenous contrast imaging in pediatric echocardiography. Pediatr Cardiol 26, 413-417 (2005)
  • Milingos S, Kallipolitis G, Stefanidis K, Sklia J, Makris N, Loutradis A, Antsaklis A, Michalas S. Saline contrast hysterosonography in infertile patients and in women with abnormal uterine bleeding. Eur J Gynaecol Oncol 26, 564-567 (2005)
  • Miller FH, Kraemer E, Dalal K, Keppke A, Huo E, Hoff FL. Unexplained renal colic: What is the utility of IV contrast?. Clin Imaging 29, 331-336 (2005)
  • Muhlenbruch G, Wildberger JE, Koos R, Das A, Thomas C, Ruhl K, Niethammer M, Floh TG, Stanzel S, Gunther RW, Mahnken AH. Calcium scoring of aortic valve calcification in aortic valve stenosis with a multislice computed tomography scanner: Non-enhanced versus contrast-enhanced studies. Acta Radiol 46, 561-566 (2005)
  • Muhs BE, Gagne P, Wagener J, Baker J, Ortega MR, Adelman MA, Cayne NS, Rockman CB, Maldonado T. Gadolinium-enhanced versus time-of-flight magnetic resonance angiography: What is the benefit of contrast enhancement in evaluating carotid stenosis?. Ann Vasc Surg 19, 823-828 (2005)
  • Nasi F, Fiocchi F, Pecchi A, Rivasi F, Torricelli P. MRI evaluation of myometrial invasion by endometrial carcinoma: Comparison between fast-spin-echo T2w and coronal FMPSPGR gadolinium-dota-enhanced sequences. Radiol Med (Torino) 110, 199-210 (2005)
  • Omata M. Can contrast-enhanced sonography be used to characterize focal hepatic lesions in patients with liver disease? (Editorial). Nat Clin Pract Gastroenterol 2, 452-453 (2005)
  • Ouwendijk R, Kock MCJM, Visser K, Pattynama PMT, De Haan MW, Hunink MGM. Interobserver agreement for the interpretation of contrast-enhanced 3D MR angiography and MDCT angiography in peripheral arterial disease. Am J Roentgenol 185, 1261-1267 (2005)
  • Oysu AS, Ayanoglu E, Kodalli N, Oysu C, Uneri C, Erzen C. Dynamic contrast-enhanced MRI in the differentiation of posttreatment fibrosis from recurrent carcinoma of the head and neck. Clin Imaging 29, 307-312 (2005)
  • Pagnan L, Tona G, Belgrano M, Cova M, Mucelli RP. Direct contrast enhanced venography MR in the study of central venous accesses in children receiving total parenteral nutrition. Radiol Med (Torino) 110, 241-248 (2005)
  • Pedersen JF, Larsen VA, Bytzer P, Madsen LG, Hamberg O. Hepatic transit time of ultrasound contrast in biopsy characterized liver disease. Acta Radiol 46, 557-560 (2005)
  • Petrik M, Weigel C, Kirsch M, Hosten N. No detectable nephrotoxic side effect using a dimer, non-ionic contrast media in cerebral perfusion computed tomography in case of suspected brain ischemia (German, English Abstract). Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 177, 1242-1249 (2005)
  • Potthast S, Schulte AC, Bongartz GM, Hugli R, Aschwanden M, Bilecen D. Low-dose intra-arterial contrast-enhanced MR aortography in patients based on a theoretically derived injection protocol. Eur Radiol 15, 2347-2353 (2005)
  • Strunk H, Borner N, Stuckmann G, Frohlich E, Hadizadeh D. Contrast-enhanced “low MI real-time” phase-inversion sonography to differentiate between malignant and benign focal liver lesions (German, English Abstract). Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 177, 1394-1404 (2005)
  • Takeshima K, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Ichikawa H, Kawachi T, Ogawa S. Comparison of IV contrast-enhanced sonography and histopathology of pancreatic cancer. Am J Roentgenol 185, 1193-1200 (2005)
  • Temmerman OPP, Heyligers IC, Teule GJJ, Hoekstra OS, Raijmakers PGHM. The value of contrast and subtraction arthrography in the assessment of aseptic loosening of total hip prostheses: A meta-analysis. Eur J Radiol 56, 113-119 (2005)
  • Tsuchiya K, Honya K, Fujikawa A, Tateishi H, Shiokawa Y. Postoperative assessment of extracranial-intracranial bypass by time-resolved 3D contrast-enhanced MR angiography using parallel imaging. Am J Neuroradiol 26, 2243-2247 (2005)
  • Unlu E, Cakir B, Gocer B, Tuncbilek N, Gedikoglu M. The role of contrast-enhanced MR angiography in the assessment of recently ruptured intracranial aneurysms: A comparative study. Neuroradiology 47, 780-791 (2005)
  • Yucel A, Gecici O, Emul M, Oyar O, Gulsoy UK, Dayanir YO, Acar M, Degirmenci B, Haktanir A. Effect of informed consent for intravascular contrast material on the level of anxiety: How much information should be given?. Acta Radiol 46, 701-707 (2005)
  • Zheng RQ, Kudo M. Hepatic angiomyolipoma: Identification of an efferent vessel to the hepatic vein by contrast-enhanced harmonic ultrasound. Br J Radiol 78, 956-960 (2005)
  • Zhu M, Zhong YM, Li YH, Sun AM, Jin B. Congenital aortic arch anomalies: Diagnosis using contrast enhanced magnetic resonance angiography. Chin Med J (Engl) 118, 1751-1753 (2005)
  • Molecular Imaging: 7. Carbon
  • Chehade F, De Labriolle-Vaylet C, Moins N, Moreau MF, Papon J, Labarre P, Galle P, Veyre A, Hindie E. Secondary ion mass spectrometry as a tool for investigating radiopharmaceutical distribution at the cellular level: The example of I-BZA and 14C-I-BZA. J Nucl Med 46, 1701-1706 (2005)
  • Farsad M, Schiavina R, Castellucci P, Nanni C, Corti B, Martorana G, Canini R, Grigioni W, Boschi S, Marengo M, Pettinato C, Salizzoni E, Monetti N, Franchi R, Fanti S. Detection and localization of prostate cancer: Correlation of 11C-choline PET/CT with histopathological step-section analysis. J Nucl Med 46, 1642-1649 (2005)
  • Freedman NMT, Mishani E, Krausz Y, Weininger J, Lester H, Blaugrund E, Ehrlich D, Chisin R. In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using 11C-L-deprenyl and PET. J Nucl Med 46, 1618-1624 (2005)
  • Gao MZ, Mock BH, Hutchins GD, Zheng QH. Synthesis and initial PET imaging of new potential dopamine D3 receptor radioligands (E)-4, 3,2-[11C]methoxy-N-4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl-cinnamoylamides. Bioorg Med Chem 13, 6233-6243 (2005)
  • Mauger G, Saba W, Hantraye P, Dolle F, Coulon C, Bramoulle Y, Chalon S, Gregoire MC. Multiinjection approach for D2 receptor binding quantification in living rats using [11C]raclopride and the β-microprobe: Crossvalidation with in vitro binding data. J Cereb Blood Flow Metab 25, 1517-1527 (2005)
  • Melo TM, Nehlig A, Sonnewald U. Metabolism is normal in astrocytes in chronically epileptic rats: A 13C NMR study of neuronal-glial interactions in a model of temporal lobe epilepsy. J Cereb Blood Flow Metab 25, 1254-1264 (2005)
  • Stehouwer JS, Plisson C, Jarkas N, Zeng FX, Voll RJ, Williams L, Martarello L, Votaw JR, Tamagnan G, Goodman MM. Synthesis, radiosynthesis, and biological evaluation of carbon-11 and fluorine-18 (N-fluoroalkyl) labeled 2β-carbomethoxy-3β-(4′-(3-furyl)phenyl)tropanes and -nortropanes: Candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. J Med Chem 48, 7080-7083 (2005)
  • 8. Fluorine
  • Aflalo-Hazan V, Gutman F, Kerrou K, Montravers F, Grahek D, Talbot JN. Increased FDG uptake by bone marrow in major β-thalassemia. Clin Nucl Med 30, 754-755 (2005)
  • Avril N, Sassen S, Schmalfeldt B, Naehrig J, Rutke S, Weber WA, Werner M, Graeff H, Schwaiger M, Kuhn W. Prediction of response to neoadjuvant chemotherapy by sequential 18F-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol 23, 7445-7453 (2005)
  • Boumezbeur F, Besret L, Valette J, Gregoire MC, Delzescaux T, Maroy R, Vaufrey F, Gervais P, Hantraye P, Bloch G, Lebon V. Glycolysis versus TCA cycle in the primate brain as measured by combining 18F-FDG PET and 13C-NMR. J Cereb Blood Flow Metab 25, 1418-1423 (2005)
  • Cheesman AL, Barker RA, Lewis SJG, Robbins TW, Owen AM, Brooks DJ. Lateralisation of striatal function: Evidence from 18F-dopa PET in Parkinson's disease. J Neurol Neurosurg Psychiatry 76, 1204-1210 (2005)
  • Chen WP, Matsunari I, Noda A, Yanase D, Yajima K, Takeda N, Yamada M, Minoshima S, Nishimura S. Rapid scanning protocol for brain 18FDG PET: A validation study. J Nucl Med 46, 1633-1641 (2005)
  • Choi JY, Lee KS, Kwon OJ, Shim YM, Baek CH, Park K, Lee KH, Kim BT. Improved detection of second primary cancer using integrated [18F] fluorodeoxyglucose positron emission tomography and computed tomography for initial tumor staging. J Clin Oncol 23, 7654-7659 (2005)
  • Costa DB, Parker JA, Schumer ST. Non-metastatic bilateral 18F fluorodeoxyglucose avid adrenal glands in non-small-cell lung cancer. J Clin Oncol 23, 7740-7742 (2005)
  • Czoty PW, Gage HD, Nader MA. PET imaging of striatal dopamine D2 receptors in nonhuman primates: Increases in availability produced by chronic raclopride treatment. Synapse 58, 215-219 (2005)
  • De Waele M, Carp L, Lauwers R, Hendriks J, De Maeseneer M, Van Schil R, Blockx R. Paravertebral schwannoma with high uptake of fluorodeoxyglucose on positron emission tomography. Acta Chir Belg 105, 537-538 (2005)
  • Dobert N, Pantel J, Frolich L, Hamscho N, Menzel C, Grunwald F. Diagnostic value of FDG-PET and HMPAO-SPET in patients with mild dementia and mild cognitive impairment: Metabolic index and perfusion index. Dement Geriatr Cogn Disord 20, 63-70 (2005)
  • Dos Santos DT, Lima ENP, Chojniak R, Cavalcanti MGP. Topographic metabolic map of head and neck squamous cell carcinoma using 18F-FDG-PET and CT image fusion. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 100, 619-625 (2005)
  • Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Siebner H, Alexopoulus P, Minoshima S, Schwaiger M, Kurz A. Prediction of individual clinical outcome in MCI by means of genetic assessment and 18FDG PET. J Nucl Med 46, 1625-1632 (2005)
  • Fukuchi K, Ishida Y, Higashi M, Tsunekawa T, Ogino H, Minatoya K, Kiso K, Naito H. Detection of aortic graft infection by fluorodeoxyglucose positron emission tomography: Comparison with computed tomographic findings. J Vasc Surg 42, 919-925 (2005)
  • Gangloff A, Hsueh WA, Kesner AL, Kiesewetter DO, Pio BS, Pegram MD, Beryt M, Townsend A, Czernin J, Phelps ME, Silverman DHS. Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with 18F-fluoropaclitaxel. J Nucl Med 46, 1866-1871 (2005)
  • Ghodsian M, Obrzut SL, Hyde CC, Watts WJ, Schiepers C. Evaluation of metastatic meningioma with 2-deoxy-2-[18F]fluoro-D-glucose PET/CT. Clin Nucl Med 30, 717-720 (2005)
  • Gontier E, Alberini JL, Wartski M, Al Nakib M, Corone C, Pecking AP. Increased 18FDG pulmonary uptake in contrast medium aspiration on PET/CT imaging. Clin Nucl Med 30, 756-757 (2005)
  • Gutte H, Hojgaard L, Kjaer A. Early clinical experience and impact of 18F-FDG PET. Nucl Med Commun 26, 989-994 (2005)
  • Installe J, Nzeusseu A, Bol A, Depresseux G, Devogelaer JP, Lonneux M. 18F-fluoride PET for monitoring therapeutic response in Paget's disease of bone. J Nucl Med 46, 1650-1658 (2005)
  • Ishimaru S, Tsujino I, Sakaue S, Oyama N, Takei T, Tsukamoto E, Tamaki N, Nishimura M. Combination of 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in assessing cardiac sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 22, 234-235 (2005)
  • Jacobson O, Bechor Y, Icar A, Novak N, Birman A, Marom H, Fadeeva L, Golan E, Leibovitch I, Gutman M, Even-Sapir E, Chisin R, Gozin M, Mishani E. Prostate cancer PET bioprobes: Synthesis of [18F]-radiolabeled hydroxyflutamide derivatives. Bioorg Med Chem 13, 6195-6205 (2005)
  • Jones-Jackson L, Walker R, Purnell G, McLaren SG, Skinner RA, Thomas JR, Suva LJ, Anaissie E, Miceli M, Nelson CL, Ferris EJ, Smeltzer MS. Early detection of bone infection and differentiation from post-surgical inflammation using 2-deoxy-2-[18F]-fluoro-D-glucose positron emission tomography (FDG-PET) in an animal model. J Orthop Res 23, 1484-1489 (2005)
  • Kamiyama Y, Aihara R, Nakabayashi T, Mochiki E, Asao T, Kuwano H, Oriuchi N, Endo K. 18F-Fluorodeoxyglucose positron emission tomography: Useful technique for predicting malignant potential of gastrointestinal stromal tumors. World J Surg 29, 1429-1435 (2005)
  • Kenny LM, Vigushin DM, Al-Nahhas A, Osman S, Luthra SK, Shousha S, Coombes RC, Aboagye EO. Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: Evaluation of analytical methods. Cancer Res 65, 10104-10112 (2005)
  • Kosters K, Bleeker-Rovers CP, Van Crevel R, Oyen WJG, Van der Ven AJAM. Aortitis diagnosed by 18F-fluorodeoxyglucose positron emission tomography in a patient with syphilis and HIV coinfection. Infection 33, 387-389 (2005)
  • Kumar R, Loving VA, Chauhan A, Zhuang HMM, Mitchell S, Alavi A. Potential of dual-time-point imaging to improve breast cancer diagnosis with 18F-FDG PET. J Nucl Med 46, 1819-1824 (2005)
  • Landheer MLEA, Steffens MG, Klinkenbijl JHG, Westenberg AH, Oyen WJG. Value of fluorodeoxyglucose positron emission tomography in women with breast cancer. Br J Surg 92, 1363-1367 (2005)
  • Lee JD, Yang WI, Park YN, Kim KS, Choi JS, Yun MJ, Ko DH, Kim TS, Cho AEH, Kim HM, Han KH, Im SS, Ahn YH, Choi CW, Park JH. Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased 18FDG uptake. J Nucl Med 46, 1753-1759 (2005)
  • Lee TJ, Lou HY, Lee CM, Hsu CH. Metastatic lymph node and osteolytic skeletal metastasis detected by FDG-PET in an endoscopy-diagnosed early-stage esophageal cancer. Clin Nucl Med 30, 760-762 (2005)
  • Ludeman N, Elicker BM, Reddy GP, Webb WR, Leung JWT, Gotway MB. Atypical rounded atelectasis: Diagnosis and management based on results of 18FDG positron emission tomography. Clin Nucl Med 30, 734-735 (2005)
  • Mach RH, Gage HD, Buchheimer N, Huang YS, Kuhner R, Wu L, Morton TE, Ehrenkaufer RL. N-[18F]4′-fluorobenzylpiperidin-4yl(2-fluorophenyl) acetamide ([18F]FBFPA): A potential fluorine-18 labeled PET radiotracer for imaging sigma-1 receptors in the CNS. Synapse 58, 267-274 (2005)
  • Mahfouz T, Miceli MH, Saghafifar F, Stroud S, Jones-Jackson L, Walker R, Grazziutti ML, Purnell G, Fassas A, Tricot G, Barlogie B, Anaissie E. 18F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: A study of 165 infectious episodes. J Clin Oncol 23, 7857-7863 (2005)
  • Neal TR, Schumann WC, Berridge MS, Landau BR. Synthesis of [18F]-6-deoxy-6-fluoro-D-glucose ([18F] 6FDG), a potential tracer of glucose transport. J Label Compound Radiopharm 48, 845-854 (2005)
  • Nimmagadda S, Mangner TJ, Sun HH, Klecker RW, Muzik O, Lawhorn-Crews JM, Douglas KA, Collins JM, Shields AF. Biodistribution and radiation dosimetry estimates of 1-(2′-deoxy-2′-18F-fluoro-1-β-D-arabinofuranosyl)-5-bromouracil: PET imaging studies in dogs. J Nucl Med 46, 1916-1922 (2005)
  • Nishiyama Y, Yamamoto Y, Yokoe K, Monden T, Sasakawa Y, Tsutsui K, Satoh K, Ohkawa M. Contribution of whole body FDG-PET to the detection of distant metastasis in pancreatic cancer. Ann Nucl Med 19, 491-497 (2005)
  • Oe A, Habu D, Kawabe J, Torii K, Kawamura E, Kotani J, Hayashi T, Sakaguchi H, Shiomi S. A case of diffuse hepatic angiosarcoma diagnosed by FDG-PET. Ann Nucl Med 19, 519-521 (2005)
  • Pan XB, Wright TG, Leong FJ, McLaughlin RA, Declerck JM, Silverman DHS. Improving influx constant and ratio estimation in FDOPA brain PET analysis for Parkinson's disease. J Nucl Med 46, 1737-1744 (2005)
  • Park YH, Baik JH, Ahn MI, Kim JY. FDG uptake in the diaphragm and crura, vocal cords, and base of tongue in a crying child. Clin Nucl Med 30, 752-753 (2005)
  • Piesman M, Hwang I, Moses FM, Allen TW. Duodenal diverticulum presenting as a hypermetabolic mass on 18FDG PET/CT. Clin Nucl Med 30, 747-748 (YR)
  • Rigacci L, Castagnoli A, Dini C, Carpaneto A, Matteini M, Alterini R, Carrai V, Nassi L, Bernardi F, Pieroni C, Bosi A. 18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: Long-term results. Oncol Rep 14, 1209-1214 (2005)
  • Seimbille Y, Czernin J, Phelps ME, Silverman DHS. Synthesis of an 18F-fluorobenzoate idarubicin derivative as new potential PET radiotracer to predict chemotherapy resistance. J Label Compound Radiopharm 48, 819-827 (2005)
  • Seimbille Y, Phelps ME, Czernin J, Silverman DHS. Fluorine-18 labeling of 6,7-disubstituted anilinoquinazoline derivatives for positron emission tomography (PET) imaging of tyrosine kinase receptors: Synthesis of 18F-Iressa and related molecular probes. J Label Compound Radiopharm 48, 829-843 (2005)
  • Shaw SW, Wang CW, Ma SY, Ng KK, Chang TC. Exclusion of lung metastases in placental site trophoblastic tumor using [18F]fluorodeoxyglucose positron emission tomography: A case report. Gynecol Oncol 99, 239-242 (2005)
  • Sojan SM, Chew G. Pneumocystis carinii pneumonia on 18FDG PET. Clin Nucl Med 30, 763-764 (2005)
  • Song SY, Kim JH, Ryu JS, Lee GTH, Kim SB, Park SI, Song HY, Cho KJ, Ahn SD, Lee SW, Shin SS, Choi EK. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer. Int J Radiat Oncol Biol Phys 63, 1053-1059 (2005)
  • Su KH, Wu LC, Liu RS, Wang SJ, Chen JC. Quantification method in [18F]fluorodeoxyglucose brain positron emission tomography using independent component analysis. Nucl Med Commun 26, 995-1004 (2005)
  • Tseng JR, Dandekar M, Subbarayan M, Cheng Z, Park JM, Louie S, Gambhir SS. Reproducibility of 3′-deoxy-3′-18F-fluorothymidine microPET studies in tumor xenografts in mice. J Nucl Med 46, 1851-1857 (2005)
  • Umeoka S, Koyama T, Saga T, Higashi T, Ito N, Kamoto T, Kotani H, Ogawa O, Togashi K. High 18F-fluorodeoxyglucose uptake in adrenal histoplasmosis; a case report. Eur Radiol 15, 2483-2486 (2005)
  • Unger JB, Ivy JJ, Ramaswamy MR, Charrier A, Connor P. Whole-body [18F]fluoro-2-deoxyglucose positron emission tomography scan staging prior to planned radical hysterectomy and pelvic lymphadenectomy. Int J Gynecol Cancer 15, 1060-1064 (2005)
  • Vranken E, Versiljpt J, Winne L, Veys EM, Hamphrey H. Adult-onset still disease: Evaluation with serial 18F fluorodeoxyglucose positron emission tomography. Clin Nucl Med 30, 740-741 (2005)
  • Wendling D, Blagosklonov O, Streit G, Lehuede G, Toussirot E, Cardot JC. FDG-PET/CT scan of inflammatory spondylodiscitis lesions in ankylosing spondylitis, and short term evolution during anti-tumour necrosis factor treatment. Ann Rheum Dis 64, 1663-1665 (YR)
  • Wong CYO, Thie J, Parling-Lynch KJ, Zakalik D, Margolis JH, Gaskill M, Hill J, Qing F, Fink-Bennett D, Nagle C. Glucose-normalized standardized uptake value from 18FDG PET in classifying lymphomas. J Nucl Med 46, 1659-1663 (2005)
  • Yago Y, Yukihiro M, Kuroki H, Katsuragawa Y, Kubota K. Cold tuberculosis abscess identified by FDG PET. Ann Nucl Med 19, 515-518 (2005)
  • Yao M, Smith RB, Graham MM, Hoffman HT, Tan HM, Funk GF, Graham SM, Chang K, Dornfeld KJ, Menda Y, Buatti JM. The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment. Int J Radiat Oncol Biol Phys 63, 991-999 (2005)
  • Yun M, Lim JS, Noh SH, Hyung WJ, Cheong JH, Bong JK, Cho A, Lee JD. Lymph node staging of gastric cancer using 18FDG PET: A comparison study with CT. J Nucl Med 46, 1582-1588 (2005)
  • Zaknun JJ, Kendler D, Moncayo R, Zur Nedden D, Virgolini I. 18FDG PET for assessing tyrosine kinase-related signal transduction inhibition in a GIST c-Kit-positive tumor patient by imatinib. Clin Nucl Med 30, 749-751 (2005)
  • 9. Gallium
  • Sugawara Y, Sakayama K, Sada E, Kajihara M, Semba T, Higashino H, Mochizuki T. Heerfordt syndrome initially presenting with subcutaneous mass lesions: Usefulness of gallium-67 scans before and after treatment. Clin Nucl Med 30, 732-733 (2005)
  • Velikyan I, Sundberg AL, Lindhe O, Hoglund AU, Eriksson O, Werner E, Carlsson J, Bergstrom M, Langstrom B, Tolmachev V. Preparation and evaluation of 68Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors. J Nucl Med 46, 1881-1888 (2005)
  • 10. Hydrogen
  • Caglar E, Sabuncuoglu H, Keskin T, Isikli S, Keskil S, Korkusuz F. In vivo human brain biochemistry after aerobic exercise: Preliminary report on functional magnetic resonance spectroscopy. Surg Neurol 64, S53-S56 (2005)
  • Pfeuffer J, Lin JC, Delabarre L, Ugurbil K, Garwood M. Detection of intracellular lactate with localized diffusion {1H-13C}-spectroscopy in rat glioma in vivo. J Magn Reson 177, 129-138 (2005)
  • Prescot AP, Dzik-Jurasz ASK, Leach MO, Sirohi L, Powles R, Collins DJ. Localized COSY and DQF-COSY 1H-MRS sequences for investigating human tibial bone marrow in vivo and initial application to patients with acute leukemia. J Magn Reson Imaging 22, 541-548 (2005)
  • Pulkkinen J, Hakkinen AM, Lundbom N, Paetau A, Kauppinen RA, Hiltunen Y. Independent component analysis to proton spectroscopic imaging data of human brain tumours. Eur J Radiol 56, 160-164 (2005)
  • Rodrigues TB, Cerdan S. A fast and sensitive 1H NMR method to measure the turnover of the H2 hydrogen of lactate. Magn Reson Med 54, 1014-1019 (2005)
  • Timonen M, Kankaanranta L, Lundbomb N, Collan J, Kangasmaki A, Kortesniemi A, Hakkinen AM, Lonngren A, Karjalainen S, Rasilainen A, Leinonen J, Huitti T, Jaaskelainen J, Kouri M, Savolainen S, Heikkinen S. 1H MRS studies in the Finnish boron neutron capture therapy project: Detection of 10B-carrier, L-p-boronophenylalanin-fructose. Eur J Radiol 56, 154-159 (2005)
  • 11. Indium
  • Broekema M, Van Eerd JJEM, Oyen WJG, Corstens FHM, Liskamp RMJ, Boerman OC, Harris TD. Synthesis of leukotriene B4 antagonists labeled with 111In or 99mTc to image infectious and inflammatory foci. J Med Chem 48, 6442-6453 (2005)
  • Conti PS, White C, Pieslor P, Molina A, Aussie J, Foster P. The role of imaging with 111In-ibritumomab tiuxetan in the ibritumomab tiuxetan (Zevalin) regimen: Results from a Zevalin Imaging Registry. J Nucl Med 46, 1812-1818 (2005)
  • De Jong M, Barone R, Krenning E, Bernard B, Melis M, Visser T, Gekle M, Willnow TE, Walrand S, Jamar F, Pauwels S. Megalin is essential for renal proximal tubule reabsorption of 111In-DTPA-octreotide. J Nucl Med 46, 1696-1700 (2005)
  • Jin Y, Kong HF, Stodilka RZ, Wells RG, Zabel P, Merrifield PA, Sykes J, Prato FS. Determining the minimum number of detectable cardiac-transplanted 111In-tropolone-labelled bone-marrow-derived mesenchymal stem cells by SPECT. Phys Med Biol 50, 4445-4455 (2005)
  • 12. Iodine
  • Eerola J, Tienari PJ, Kaakkola S, Nikkinen P, Launes J. How useful is [123I] β-CIT SPECT in clinical practice?. J Neurol Neurosurg Psychiatry 76, 1211-1216 (2005)
  • Koch W, Hamann C, Welsch J, Popperl G, Radau PE, Tatsch K. Is iterative reconstruction an alternative to filtered backprojection in routine processing of dopamine transporter SPECT studies?. J Nucl Med 46, 1804-1811 (2005)
  • Mateos JJ, Lomena F, Parellada E, Font M, Fernandez E, Pavia J, Prats A, Pons F, Bernardo M. Decreased striatal dopamine transporter binding assessed with [123I] FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism. Psychopharmacology (Berl) 181, 401-406 (2005)
  • 13. Phosphorus
  • Giannesini B, Izquierdo M, Le Fur Y, Cozzone PJ, Fingerle J, Himber J, Kunnecke B, Von Kienlin M, Bendahan D. New experimental setup for studying strictly noninvasively skeletal muscle function in rat using 1H-magnetic resonance (MR) imaging and 31P-MR spectroscopy. Magn Reson Med 54, 1058-1064 (2005)
  • Mancini L, Payne GS, Leach MO. Implementation and evaluation of CSI-localized J crosspolarization for detection of 31P magnetic resonance spectra in vivo. Magn Reson Med 54, 1065-1071 (2005)
  • 14. Technetium
  • Buyukdereli G, Guney IB, Seydaoglu G. Effectiveness of diuretic injection on the measurement of differential renal function using 99mTc DMSA in patients with a dilated renal pelvis. Clin Nucl Med 30, 721-724 (2005)
  • Einollahi B, Bakhtiari P, Simforoosh N, Amirjaiali R, Bassiri A, Nafar M, Pour-Reza-Gholi F, Firouzan A, Lessan-Pezeshki M, Khatami MR, Nourbala MH, Pourfarzini V. Renal allograft accumulation of technetium-99m sulfur colloid as a predictor of graft rejection. Transplant Proc 37, 2973-2975 (2005)
  • Elhendy A, Huurman A, Schinkel AFL, Bax JJ, Van Domburg RT, Valkema R, Biagini E, Poldermans D. Association of ischemia on stress 99mTc-tetrofosmin myocardial perfusion imaging with all-cause mortality in patients with diabetes mellitus. J Nucl Med 46, 1589-1595 (2005)
  • Guldiken S, Tugrul A, Altiay G, Hacimahmutoglu S, Durmus-Altun G. Clearance of technetium-99m-labeled DTPA in hyperthyroidism without clinical evidence of lung disease, and relation to pulmonary function. Ann Nucl Med 19, 523-527 (2005)
  • Haneline M, Nansel DD. Changes in cerebellar blood flow after manipulation of the cervical spine using technetium Tc 99m ethyl cysteinate dimer (Letter). J Manipulative Physiol Ther 28, 548 (2005)
  • Cagnie B. Changes in cerebellar blood flow after manipulation of the cervical spine using technetium Tc 99m ethyl cysteinate dimer (Response). J Manipulative Physiol Ther 28, 548-549 (2005)
  • Cooperstein R. Changes in cerebellar blood flow after manipulation of the cervical spine using technetium 99m-ethyl cysteinate dimer (Letter). J Manipulative Physiol Ther 28, 549-550 (2005)
  • Cagnie B. Changes in cerebellar blood flow after manipulation of the cervical spine using technetium 99m-ethyl cysteinate dimer (Response). J Manipulative Physiol Ther 28, 550 (2005)
  • Huynh LT, Kim SY, Murphy TF. The typical appearance of focal nodular hyperplasia in triple-phase CT scan, hepatobiliary scan and Tc-99m sulfur colloid scan with SPECT. Clin Nucl Med 30, 736-739 (2005)
  • Ito K, Sugihara H, Kinoshita N, Azuma A, Matsubara H. Assessment of Takotsubo cardiomyopathy (transient left ventricular apical ballooning) using 99mTc-tetrofosmin, 123I-BMIPP, 123I-MIBG and 99mTc-PYP myocardial SPECT. Ann Nucl Med 19, 435-445 (2005)
  • Mathur A, Mallia MB, Subramanian S, Banerjee S, Kothari K, Dhotare B, Sarma HD, Venkatesh M. 99mTcN complexes of tert-butyl dithiocarbamate and methoxyisobutyl dithiocarbamate as myocardial and brain imaging agents. Nucl Med Commun 26, 1013-1019 (2005)
  • Nock BA, Maina T, Behe M, Nikolopoulou A, Gotthardt M, Schmitt JS, Behr TM, Macke HR. CCK-2/gastrin receptor-targeted tumor imaging with 99mTc-labeled minigastrin analogs. J Nucl Med 46, 1727-1736 (2005)
  • Okudan B, Sahin M, Ozbek FM, Keskin AU, Cure E. Detection of alveolar epithelial injury by 99mTc DTPA radioaerosol inhalation lung scan in rheumatoid arthritis patients. Ann Nucl Med 19, 455-460 (2005)
  • Okudan B, Ozbek FM, Dogan A, Ozturk B, Yildiz M. Evaluation of the effect of trimetazidine on 99mTc methoxyisobutyl isonitrile gated scintigraphy in patients with coronary artery ectasia. Saudi Med J 26, 1573-1578 (2005)
  • Pilecki S, Gierach M, Pufal J, Jankowska K, Wysocki M, Kurylak A, Walek S, Junik R. Accumulation of 99mTc DTPA in Ewing sarcoma. Clin Nucl Med 30, 771-772 (2005)
  • Rogers BE, Parry JJ, Andrews R, Cordopatis P, Nock BA, Maina T. MicroPET imaging of gene transfer with a somatostatin receptor-based reporter gene and 94mTc-Demotate 1. J Nucl Med 46, 1889-1897 (2005)
  • Tousek P, Orban M, Martinoff S, Firschke C. Assessment of infarcted myocardium with real time myocardial contrast echocardiography: Comparison with technetium-99m sestamibi single photon emission computed tomography. Heart 91, 1568-1572 (2005)
  • Villa G, Balleari E, Carletto M, Grosso M, Clavio M, Piccardo A, Rebella L, Tommasi L, Morbelli S, Peschiera F, Gobbi M, Ghio R. Staging and therapy monitoring of multiple myeloma by 99mTc-sestamibi scintigraphy: A five year single center experience. J Exp Clin Cancer Res 24, 355-361 (2005)
  • Vittorini E, Del Giudice E, Pizzoli A, Caudana R. MRI versus scintigraphy with 99mTc-HMPAO-labelled granulocytes in the diagnosis of bone infection (Italian, English Abstract). Radiol Med (Torino) 109, 395-403 (2005)
  • Wang J, Jiang YP, Liu XD, Chen ZP, Yang LQ, Liu CJ, Xiang JD, Su HL. 99mTc-TRODAT-1 SPECT study in early Parkinson's disease and essential tremor. Acta Neurol Scand 112, 380-385 (2005)
  • Zantut-Wittmann DE, Ramos CD, Santos AO, Lima MMO, Panzan AD, Facuri FO, Etchebehere ECSC, Lima MCL, Tambascia MA, Camargo EE. High pre-therapy [99mTc]pertechnetate thyroid uptake, thyroid size and thyrostatic drugs: Predictive factors of failure in [131I]iodide therapy in Graves' disease. Nucl Med Commun 26, 957-963 (2005)
  • 15. Others
  • Bouvet M, Spernyak J, Katz MH, Mazurchuk RV, Takimoto S, Bernacki R, Rustum YM, Moossa AR, Hoffman RM. High correlation of whole-body red fluorescent protein imaging and magnetic resonance imaging on an orthotopic model of pancreatic cancer. Cancer Res 65, 9829-9833 (2005)
  • Cho SY, Ravasi L, Szajek LP, Seidel J, Green MV, Fine HA, Eckelman WC. Evaluation of 76Br-FBAU as a PET reporter probe for HSV1-tk gene expression imaging using mouse models of human glioma. J Nucl Med 46, 1923-1930 (2005)
  • Kjaer A, Lebech AM, Hesse B, Petersen CL. Right-sided cardiac function in healthy volunteers measured by first-pass radionuclide ventriculography and gated blood-pool SPECT: Comparison with cine MRI. Clin Physiol Funct Imaging 25, 344-349 (2005)
  • Marie PY, Djaballah W, Franken PR, Vanhove C, Muller MA, Boutley H, Poussier S, Olivier P, Karcher G, Bertrand A. OSEM reconstruction, associated with temporal Fourier and depth-dependant resolution recovery filtering, enhances results from sestamibi and 201Tl 16-interval gated SPECT. J Nucl Med 46, 1789-1795 (2005)
  • Perk LR, Visser GWM, Vosjan MJWD, Stigter-van Walsum M, Tijink BM, Leemans CR, Van Dongen GAMS. 89Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals 90Y and 117Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med 46, 1898-1906 (2005)
  • Schulz GM, Varga M, Jeffires K, Ludlow CL, Braun AR. Functional neuroanatomy of human vocalization: An H215O PET study. Cereb Cortex 15, 1835-1847 (2005)
  • Sohlberg A, Jolkkonen I, Ruotsalainen U, Kuikka JT. Imaging D2-receptors in quinolinic acid lesioned rat striatum with high resolution pinhole SPECT. Nuklearmedizin 44, N43-N45 (2005)